Information Provided By: 
Fly News Breaks for March 3, 2020
FATE
Mar 3, 2020 | 09:32 EDT
BMO Capital analyst Do Kim raised the firm's price target on Fate Therapeutics to $28 from $22 after its Q4 earnings beat, noting that the narrower than expected loss was due to the company's higher collaboration revenues. The analyst also contends that the company is making steady progress with multiple IND filings for next-gen iPSCs, but he sees greater downside risk to FT500/FT516 clinical updates, keeping his Market Perform rating on the shares.
News For FATE From the Last 2 Days
There are no results for your query FATE
